Myelodysplastic disorders carrying both isolated del(5q) and JAK2V617F mutation: concise review, with focus on lenalidomide therapy

Abstract: The concomitant presence of del(5q) and JAK2V617F mutation is an infrequent event which occurs in rare patients with peculiar cytogenetic, molecular, morphological and clinical features, resembling those of both myelodysplastic syndromes and myeloproliferative neoplasms. Lenalidomide may induce rapid, profound, and long-lasting responses in a subset of these patients. However, the mechanism(s) by which the drug acts in these conditions remain not completely elucidated. A new case report and a review of all cases published so far in this setting are provided. Furthermore, the possibility of categorizing – from a clinical, pathological, and biological point of view – for at least some of these patients as a potential distinct entity is discussed.

Keywords: myelodysplastic syndromes, myeloproliferative neoplasms, lenalidomide, del(5q), JAK2, World Health Organization

Introduction

The interstitial deletion of the long arm of chromosome 5 – del(5q) – is the most frequent cytogenetic abnormality occurring in myelodysplastic syndromes (MDS).1 It may present as the sole karyotype aberrancy (sometimes within a clinical picture defined as “5q– syndrome” and characterized by a favorable prognosis) or variously combined with other single or multiple chromosomal alterations.2 Complex karyotypes including del(5q), especially if associated with the presence of marrow blasts, confer to MDS patients a poor prognosis.3-5 From a therapeutic point of view, lenalidomide induces high rates of hematological and cytogenetic responses in anemic, low/intermediate-1-risk MDS patients with isolated del(5q).4

JAK2 is involved in cellular growth factor signaling, and deregulation of JAK2 by chromosomal aberrations may contribute to leukemogenesis. JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is mostly seen in JAK2V617F mutation, an activating point mutation in the JH2 domain, is most
Along with RARS associated with marked thrombocytosis, the 2008 World Health Organization’s proposed revision of MDS classification also recognized other cases showing overlaps in morphological, clinical, laboratory, and genetic aspects; in particular, rare MDS with concomitant JAK2^{V617F} mutation and isolated del(5q) were identified.6

Presented here is a brief review on this last topic, starting with the description of a paradigmatic patient who experienced a complete and long-lasting hematological, cytogenetic, and molecular response to lenalidomide.

Case presentation

In February 2010, an 84-year-old man with a previous history of acute myocardial infarctions and peptic ulcer was diagnosed as having both MDS with del(5q) and JAK2^{V617F}-positive ET in another hospital. Because of relevant thrombocytosis (1,285×10^9/L), anemia (hemoglobin 80 g/L), and erythromelalgia of the lower limbs, he was initially given hydroxyurea (1 g daily orally) plus aspirin and packed red cell transfusions. Due to a progressive increase of platelet count and worsening of anemia, hydroxyurea was substituted by pipobroman (50 mg daily orally).

In September 2011, the patient was admitted to the authors’ institute. At entry, hemoglobin level was 66 g/L, mean corpuscular volume 100 fl, platelet count 1,021×10^9/L, and white blood cell count 4.6×10^9/L with normal differential. Uric acid was 9.4 mg/dL and a “cystic complex” was found in the right kidney by ultrasound and computed tomography scan. Physical examination did not reveal enlargement of liver or spleen. The bone marrow aspirate was found moderately hypercellular and containing numerous atypical megakaryocytes, mainly characterized by hypolobated nuclei (Figure 1A and B). Blast cells were <1% of global cellularity. No ring sideroblasts were evidenced by Perls’ staining. Histological bone marrow examination confirmed a marked hyperplasia of morphologically abnormal megakaryocytes, which were similar to those observed in the “5q – syndrome”, with slightly reduced erythropoiesis and granulopoiesis, blast cells <5%, and a weak reticulin network (Figure 1D–F).

Both conventional cytogenetic and fluorescence in situ hybridization confirmed the presence of del(5q)(q13q31) as the unique chromosomal abnormality in 25% of metaphases and 50% of analyzed cells, respectively. At molecular level, BCR/ABL1 rearrangement was negative, while the JAK2^{V617F} mutation was identified by quantitative reverse transcriptase polymerase chain reaction (26.28%). SF3B1 (exons 13, 14, 15, and 16), as well as SRSF2 (P95–), U2AF1 (S34), IDH1 (R132–), IDH2 (R140– and R172–), and DNMT3A (R882–) genes were analyzed by Sanger sequencing (kinetic 3.1), as previously reported;11 all these genes were found to be not mutated.

According to the World Health Organization, a diagnosis of MDS with isolated del(5q) and JAK2^{V617F} mutation was made. The patient initially received packed red cell transfusions and a treatment with anagrelide (500 mg/day); this drug, however, was poorly tolerated.

In October 2011, the patient started lenalidomide 10 mg daily orally for 21 days every 28 days on the basis of a national, named-patient program (data not shown). The drug was well tolerated and platelet count declined rapidly, while hemoglobin levels were raised just after the first month of therapy (hemoglobin 106 g/L and platelet count 231×10^9/L); a substantially normal whole blood cell count, including disappearance of macrocytosis, was reached 3 months later (Figure 2). Erythromelalgia of the lower limbs also disappeared during the first weeks of therapy.

After 6 months of lenalidomide, a complete morphological, cytogenetic, and molecular re-evaluation showed the absence of del(5q) in both cytogenetic and fluorescence in situ hybridization analysis, as well as a remarkable reduction of JAK2^{V617F} mutation by quantitative polymerase chain reaction (0.0215%) (Figure 2). Sequential bone marrow aspirates documented progressive disappearance of atypical megakaryocytes, decrease of cellularity, and the scattered presence of focal polyclonal lymphocyte infiltration (Figure 1C). During the following months, hematological values remained substantially normal, while monitoring of JAK2^{V617F} mutation evidenced a complete molecular remission (allele burden 0%) in two subsequent controls. At the last follow-up (August 2013), after about 2 years of lenalidomide therapy, hematological values were stable and JAK2^{V617F} mutation undetectable.

Review

Concomitant presence of del(5q) and JAK2^{V617F} mutation: incidence and origin

Looking to the scarce available literature, JAK2^{V617F} mutation was first found in six MDS patients with isolated del(5q) – five with refractory cytopenia with multilineage dysplasia and one with RARS among a total of 97 MDS patients (6.2%), sixteen of whom had additional chromosomal abnormalities.12 JAK2^{V617F} mutant cases showed a trend toward a higher platelet (3/6 >700×10^9/L) and white blood cell count, as well as a moderate to marked increase in bone marrow cellularity. No response to recombinant human
Myelodysplastic disorders with isolated del(5q) and JAK2V617F mutation

Erythropoietin was observed in two of these patients with red cell transfusion-dependent disease, while hydroxycarbamide or anagrelide were employed in two additional patients with elevated thrombocytosis.

In another series from the Mayo Clinic, JAK2V617F mutation was detected in five out of 78 (6.4%) MDS patients carrying isolated del(5q); allele burden ranged from 1%–10% and no significant relevance on clinical phenotype, blood counts, or prognosis was found. Interestingly, one of these patients also showed the presence of MPLW55L mutation. In a subsequent study, the same group found that the incidence of JAK2V617F by mutation screening was 14.5% in 138 patients with isolated del(5q), including higher risk MDS variants and some cases of acute myeloid leukemia or MPN. In one patient with PV, an additional mutation of JAK2 exon 12 was found. In this study, leukocytosis, higher blast count, and IDH mutation – but not JAK2V617F mutation – negatively affected the prognosis of patients with myeloid malignancies carrying isolated del(5q).

More recently, using a highly sensitive molecular method, Geyer et al found evidence of heterozygous JAK2V617F mutation in four out of 17 (23.5%) newly diagnosed MDS patients with del(5q). One of these patients had del(5q) as single anomaly (“5q– syndrome”). In another one with refractory cytopenia.

Figure 1 (A and B) Light microscopy examination of marrow aspirate at baseline (May Grünwald–Giemsa) showing atypical, hypolobated megakaryocytes (A: original magnification ×50; B: original magnification ×100). (C) After 6 months of lenalidomide therapy, abnormal megakaryocytes disappeared and a scattered lymphocyte infiltration was seen (original magnification ×100). (D–F) Bone marrow trephine image at baseline demonstrating increased cellularity with numerous atypical hypolobated megakaryocytes (D: original magnification ×20, hematoxylin–eosin; E: original magnification ×10, immunoperoxidase staining for von Willebrand factor). Only a few reticulin fibers were present (F: original magnification ×20, reticulin staining).
Table 1 Summary of published cases of hematological disorders with concomitant presence of del(5q) and JAK2V617F mutation treated with lenalidomide

<table>
<thead>
<tr>
<th>Ref</th>
<th>Age/sex</th>
<th>Diagnosis</th>
<th>Previous treatment</th>
<th>Lenalidomide</th>
<th>Hb pre/post (g/L)</th>
<th>Platelet count pre/post (x10^9/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>85/F</td>
<td>MDS</td>
<td>Transfusions</td>
<td>10 mg/day for 21 days every 28 days plus aspirin</td>
<td>79*/1129</td>
<td>971/161</td>
</tr>
<tr>
<td>20</td>
<td>54/F</td>
<td>MDS, low IPSS risk</td>
<td>Hydroxycarbamide</td>
<td>10 mg/day for 21 days every 28 days plus G-CSF</td>
<td>88*/127</td>
<td>1,482/110</td>
</tr>
<tr>
<td></td>
<td>This case report</td>
<td>MDS with isolated del(5q) and JAK2V617F</td>
<td>Transfusions</td>
<td>10 mg/day for 21 days every 28 days</td>
<td>66*/116</td>
<td>1,021/186</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hydroxycarbamide</td>
<td>Pipobroman, anagrelide</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>82/F</td>
<td>AML from MDS</td>
<td>None</td>
<td>10 mg/day</td>
<td>99/&quot;normal&quot;</td>
<td>Not reported/&quot;normal&quot;</td>
</tr>
<tr>
<td>22</td>
<td>75/M</td>
<td>Post-PV MF</td>
<td>Phlebotomy</td>
<td>10 mg/day for 6 months</td>
<td>94/156</td>
<td>831/101</td>
</tr>
<tr>
<td>22</td>
<td>69/F</td>
<td>Post-PV MF</td>
<td>Phlebotomy</td>
<td>10 mg/day, then 5 mg/day</td>
<td>121/149</td>
<td>130/120</td>
</tr>
<tr>
<td>22</td>
<td>63/M</td>
<td>PMF</td>
<td>Recombinant human erythropoietin</td>
<td>10 mg/day, then 5 mg/day</td>
<td>TD/145</td>
<td>351/160</td>
</tr>
<tr>
<td>15</td>
<td>34/F</td>
<td>Post-PV MF</td>
<td>Pomalidomide Chlorambucil Hydroxycarbamide</td>
<td>Not specified</td>
<td>64/&quot;no response&quot;</td>
<td>16/&quot;no response&quot;</td>
</tr>
</tbody>
</table>

Notes: *Macrocytosis; /proportion of mutant alleles not available; °relapse as acute erythroleukemia with complex karyotype, reappearance of JAK2V617F mutation, and no response to lenalidomide retreatment; “disappearance of constitutional symptoms; “Improvement of anemia, neutropenia, thrombocytopenia, and splenomegaly after treatment with CEP-701 (JAK2 inhibitor).

Abbreviations: AML, acute myeloid leukemia; G-CSF, granulocyte colony-stimulating factor; Hb, hemoglobin; IPSS, International Prognostic Scoring System; MDS, myelodysplastic syndrome; MF, myelofibrosis; PMF, primary myelofibrosis; PV, polycythemia vera; Ref, reference; F, female; M, male; TD, transfusion dependent.
with multilineage dysplasia it was associated with trisomy 8. The remaining two patients (one with refractory anemia with blast excess-type 2 and one with therapy-related MDS) showed del(5q) or monosomy 5, respectively, within the context of a complex karyotype. Of note, marrow proliferative features were seen only in the first two patients.

Among MPN, del(5q) can be only rarely found in MF. A retrospective review of 939 cases identified only eight patients (0.8%) who carried del(5q), three of whom also showed JAK2(V617F) mutation. All three of these patients (one post-ET MF, one post-PV MF, and one PMF) had a complex karyotype and two of them had an excellent response to anti-JAK2 inhibitors. A literature review indicated that isolated del(5q) is also uncommon in JAK2(V617F)-positive ET. In these cases, the disease often shows mixed features of both ET and “5q− syndrome”. Interestingly, in a retrospective analysis performed within a single center in Hong Kong, the occurrence of JAK2(V617F) was found particularly high (three out of eight patients, 37.5%) in the Chinese female MDS population with isolated del(5q), thus suggesting a possible ethnic effect. Two of these patients had “5q− syndrome” and one had refractory cytopenia with multilineage dysplasia.

From a biological point of view, Ingram et al investigated a MDS patient with JAK2(V617F) mutation and isolated del(5q) by processing progenitor cell cultures (granulocyte/monocyte colony-forming units and erythropoietin-independent erythroid burst-forming units) as well as fractionated CD34+ progenitor cells, using cytogenetic and molecular approaches. Although the results of this report raise the potential that some CD34+ cells may harbor both genetic defects, genetic derivation of the clones was not investigated. Indeed, although these authors evidenced that JAK2(V617F) mutation may be an early event in these patients arising in a pluripotent stem cell and that del(5q) may be present in the same CD34+ progenitor cells, they also noticed that not all del(5q) cells are necessarily JAK2(V617F) mutant.

More recently, Sokol et al investigated the clonal origin of JAK2(V617F) mutation in a patient with del(5q) MDS presenting with thrombocytosis and normal hemoglobin. These authors detected the presence of both genetic abnormalities

<table>
<thead>
<tr>
<th>Splenomegaly</th>
<th>Cytogenetics pre/post (% abnormal metaphases)</th>
<th>JAK2(V617F) pre/post (% allele burden)</th>
<th>Bone marrow pre/post</th>
<th>Duration of response</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>Isolated del(5q) 90/24</td>
<td>Positive°/not reported</td>
<td>Increased cellularity with hypolobated megakaryocytic hyperplasia, ring sideroblasts not reported/normocellular with 30% of normal megakaryocytes and mild eosinophila increase</td>
<td>&gt;9 months</td>
</tr>
<tr>
<td>No</td>
<td>Isolated del(5q) 75/0</td>
<td>18.74/0.017</td>
<td>Rich cellularity with moderate trilineage dysplasia, erythroid hypoplasia, and outstanding large mononuclear megakaryocytic hyperplasia, no ring sideroblasts/normocellular with increased cellularity and morphology</td>
<td>&gt;15 months</td>
</tr>
<tr>
<td>No</td>
<td>Isolated del(5q) 25/0</td>
<td>26.28/0</td>
<td>High cellularity with most megakaryocytes resembling 5q− syndrome, no significant increase of reticulin network, no sideroblasts/reduction of atypical megakaryocytes, decrease of cellularity, focal polyclonal lymphocytes</td>
<td>&gt;23 months</td>
</tr>
<tr>
<td>Not reported</td>
<td>Isolated del(5q) 55/0</td>
<td>Positive°/not reported</td>
<td>34% myeloblasts/5% myeloblasts</td>
<td>5 months</td>
</tr>
<tr>
<td>Yes/reduced after lenalidomide</td>
<td>Isolated del(5q) 100/0</td>
<td>4/1</td>
<td>Post-PV MF/resolution of hypercellularity, abnormal megakaryopoiesis, and myelofibrosis</td>
<td>21 months</td>
</tr>
<tr>
<td>Yes/reduced after lenalidomide</td>
<td>Complex karyotype including monosomy 5 95/55</td>
<td>&gt;80/8</td>
<td>Cellularity 90%, reticulin fibrosis 3%/cellularity 60%, reticulin fibrosis 1–2° ^</td>
<td>&gt;12 months</td>
</tr>
<tr>
<td>No</td>
<td>Isolated del(5q) 85/30</td>
<td>4/4</td>
<td>Cellularity 80%, reticulin fibrosis 3%/cellularity 50%, reticulin fibrosis 1°</td>
<td>&gt;14 months</td>
</tr>
<tr>
<td>Yes/not reported after lenalidomide</td>
<td>Complex karyotype including del(5q) Unspecified/ not reported</td>
<td>Positive°/not reported</td>
<td>Post-PV MF/not reported</td>
<td>No response</td>
</tr>
</tbody>
</table>
del(5q) and JAK2*V617F early in the course of disease, before the development of anemia. Furthermore, although cytogenetic analysis revealed the del(5q) in 15%–30% of bone marrow metaphases, fluorescence in situ hybridization analysis of progenitor colonies identified no clonalogenic cells harboring the cytogenetic abnormality despite demonstration of the JAK2*V617F mutation. Interestingly, in this study JAK2*V617F mutation was detected in at least two distinct multipotent stem cell progeny that lacked del(5q), suggesting that del(5q) and JAK2*V617F existed in progenitors derived from genetically independent clones. The evidence of JAK2*V617F clones lacking del(5q) implies independent acquisition of the genetic abnormalities in discordant clones; however, this does not completely exclude the possibility that both del(5q) and JAK2*V617F clones may emerge as progeny of a genetically unstable hierarchal stem cell.

Effects of lenalidomide in patients with concomitant presence of del(5q) and JAK2*V617F mutation

Lenalidomide is a very effective treatment for lower risk MDS with isolated del(5q). However, the efficacy of lenalidomide as a single agent in MDS with isolated del(5q) and JAK2*V617F mutation has been described in only two patients so far (Table 1).20,21 Interestingly, in addition to good response to lenalidomide, the posted two cases and current case also shared morphological and clinical features, such as macrocytic anemia, remarkable thrombocytosis, no splenomegaly, hypercellular marrow with increased number of hypolobated megakaryocytes, no evidence of relevant fibrosis or ring sideroblasts, and a favorable outcome.

Regarding patients with other types of disease (Table 1), a transient, near complete hematological response and a complete cytogenetic remission after lenalidomide monotherapy was observed in an elderly female patient with minimally differentiated acute myeloid leukemia arising from a JAK2*V617F-positive, del(5q)(q13q33) MDS.22 The treatment was administered for 5 months and was then followed by progression with clonal evolution. Lenalidomide therapy also induced cytogenetic and molecular remissions in three patients with JAK2*V617F-positive MF (two with isolated del[5q] and one with chromosome 5 monosomy plus other cytogenetic abnormalities).23 Two of these patients had post-MPN MF and one had PMF. Marked improvement of anemia was seen in these subjects, one of whom had been already reported,9 while splenomegaly significantly reduced when present. One patient experienced a complete cytogenetic remission and two experienced a partial cytogenetic remission. Bone marrow JAK2*V617F allele burden decreased in two patients. Remission was maintained after >1 year of treatment in two cases, while the third subject developed a picture of acute erythroleukemia which did not respond to retreatment with lenalidomide. Finally, one patient with post-PV MF, JAK2*V617F mutation, and del(5q) in the context of a complex karyotype, did not respond at all to lenalidomide but had a dramatic improvement of cytopenia and splenomegaly after administration of CEP-701 anti-JAK2 inhibitor.16 Interestingly, complete hematological response, disappearance of constitutional symptoms and improvement in marrow fibrosis was observed after lenalidomide therapy in a 54-year-old female patient with post-ET MF carrying a double cytogenetic abnormality (del[5q] and t[1;12]) associated with MPL mutation but not JAK2*V617F mutation. The response was longer than 3 years, although the patient did not achieve cytogenetic response and del(5q) abnormality was persistently detected in serial bone marrow analyses.16

### Table 2 Main characteristics of myelodysplastic disorders with concomitant del(5q) and JAK2*V617F mutation

<table>
<thead>
<tr>
<th>Cytogenetics</th>
<th>Genetics</th>
<th>Clinical findings</th>
<th>Marrow morphology</th>
<th>Abbreviations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Isolated del(5q)</td>
<td>• JAK2*V617F mutation (moderate allele burden)</td>
<td>• Macrocytic anemia</td>
<td>• Increased cellularity</td>
<td>ET, essential thrombocytemia; MF, myelofibrosis; PMF, primary myelofibrosis; PV, polycythemia vera.</td>
</tr>
<tr>
<td>• Relevant thrombocytosis</td>
<td></td>
<td>• Increased number of atypical, hypolobated megakaryocytes</td>
<td>• Increased number of atypical, hypolobated megakaryocytes</td>
<td></td>
</tr>
<tr>
<td>• No splenomegaly</td>
<td></td>
<td>• Absence of ring sideroblasts</td>
<td>• No significant fibrosis (PMF or post-PV/ET MF should be excluded)</td>
<td></td>
</tr>
<tr>
<td>• No constitutional symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Favorable prognosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Conclusion

The simultaneous presence of del(5q) and JAK2*V617F mutation is a rare event which occurs prevalently in patients with a possibly “mixed” and still not well-defined MDS/MPN disorder. However, it would seem possible to identify some cases characterized by peculiar cytogenetic, molecular, morphological, and clinical findings (Table 2) and a relatively favorable prognosis (the first three patients of Table 1). The mechanism(s) by which lenalidomide seems to be particularly able to induce rapid and long-lasting responses in these
conditions are still not completely understood. As in other neoplastic disorders, lenalidomide could suppress the malignant clone(s) by a direct cytotoxic effect or by an indirect immunomodulatory activity. According to the hypothesis of two genetic aberrations overlapping in the same clone, the efficacy of lenalidomide in suppressing the del(5q) clone would induce a parallel reduction of JAK2V617F allele burden. Alternatively, in the case of an independent acquisition of the two genetic abnormalities, a different activity of lenalidomide on the JAK2V617F mutated clone should be hypothesized as probably it occurs in patients with JAK2V617F-positive MF0,10 or RARS associated with marked thrombocytosis24,25 who may show variable clinical and molecular responses to lenalidomide but are not harboring del(5q). Both these mechanisms, however, could be not mutually exclusive.

It is probably too early to categorize MDS with concomitant evidence of del(5q) and JAK2V617F mutation as a distinct entity and more work is needed to draw definitive conclusions. However, combined cytogenetic and molecular screening of these markers in patients who clinically correspond to those already described should be recommended in order to improve clinical management and biological knowledge in this field.

Acknowledgments
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Author contributions
PM and GD wrote the paper, followed the patient and analyzed the literature. VS, GM, and FLR collected and reviewed literature data. RG clinically followed the patient. GB, VG, EF, and MTV performed molecular studies. FN, PS, and CM performed cytogenetic studies. AVL performed histological studies. All authors gave substantial contributions to conception and design, took part in drafting the article or revising it critically for important intellectual content, gave final approval of the version to be published; and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved.

Disclosure
PM and MTV received honoraria from Celgene, the manufacturer of Revlimid (lenalidomide). CM received research funds from Celgene. The other authors report no conflicts of interest in this work.

References